• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 - Product Image

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

  • Published: April 2012
  • 85 pages
  • GlobalData

FEATURED COMPANIES

  • F. Hoffmann-La Roche
  • Ipsen SA
  • Novartis AG
  • MORE

Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, “Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global neuroendocrine carcinoma market. The report identifies the key trends shaping and driving the market. It also provides insights on the prevalent competitive landscape and the emerging players that are expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global neuroendocrine carcinoma sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the global neuroendocrine carcinoma therapeutics market was worth $127m in 2011 and is forecast to grow at Compound Annual Growth Rate (CAGR) of 17.9% to reach $475m by 2019. The high growth is primarily READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Neuroendocrine Carcinoma Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Risk Factors
2.4 Etiology
2.5 Symptoms
2.6 Diagnosis
2.7 Staging
2.8 Treatment and Management Pattern
2.8.1 Treatment Algorithm
2.8.2 Treatment for GI Carcinoid Tumors
2.8.3 Treatment for Pancreatic NETs/Islet Cell Tumor
2.9 Referral Pathway for GEP-NETs
2.10 GlobalData Pipeline Report Guidance
3 Neuroendocrine Carcinoma Therapeutics- Market Characterization
3.1 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Global
3.2 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) – Global
3.3 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – the US
3.4 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the US
3.5 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) –the UK
3.6 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -the UK
3.7 Neuroendocrine Carcinoma Therapeutics Market Size (2005-2010)- France
3.8 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - France
3.9 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Germany
3.10 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Germany
3.11 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Italy
3.12 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) -Italy
3.13 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) - Spain
3.14 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Spain
3.15 Neuroendocrine Carcinoma Therapeutics Market Size (2006-2011) – Japan
3.16 Neuroendocrine Carcinoma Therapeutics Market Forecast (2011-2019) - Japan
3.17 Drivers and Barriers for Neuroendocrine Carcinoma Therapeutics Market
3.17.1 Drivers for the Neuroendocrine Carcinoma Therapeutics Market
3.17.2 Barriers for the Neuroendocrine Carcinoma Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.19.1 Gastrointestinal carcinoid (NETs)
3.19.2 Pancreatic NETs
3.20 Key Takeaway
4 Neuroendocrine Carcinoma Therapeutics Market- Competitive Assessment
4.1 Overview
4.1.1 Strategic Competitor Assessment
4.2 Product Profiles for the Major Marketed Products in Neuroendocrine Carcinoma
4.2.1 Afinitor (everolimus, RAD001)
4.2.2 Sutent (sunitinib)
4.2.3 Sandostatin LAR (octreotide acetate)
4.3 Key Takeaway
5 Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Analysis by Phase of Development
5.3.1 Neuroendocrine Carcinoma Therapeutics - Phase III Pipeline
5.3.2 Neuroendocrine Carcinoma Therapeutics - Phase II Pipeline
5.3.3 Neuroendocrine Carcinoma Therapeutics- Phase I Pipeline
5.3.4 Neuroendocrine Carcinoma Therapeutics - Preclinical Pipeline
5.4 Neuroendocrine Carcinoma Therapeutics- Clinical Pipeline by Mechanism of Action
5.5 Technology Trends Analytic Framework
5.6 Neuroendocrine Carcinoma Therapeutics - Key Late Stage Pipeline Drugs in Clinical Development
5.7 Molecule Profile for Key Late Stage Pipeline Drugs under Clinical Development
5.7.1 Avastin (bevacizumab)
5.7.2 Lutathera ([177Lutetium]-DOTA0-Tyr3-Octreotate)
5.7.3 Paseriotide (SOM 230)
5.7.4 Somatuline Autogel (lanreotide acetate)
5.8 Key Takeaway
6 Neuroendocrine Carcinoma Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (The US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Neuroendocrine Carcinoma Therapeutics Clinical Trials
7 Neuroendocrine Carcinoma Therapeutics- Strategic Assessment
7.1 Future Market Competition Scenario
8 Neuroendocrine Carcinoma Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles for the Promising Drugs
8.2.1 Advanced Accelerator Applications S.A
8.2.2 Novartis AG
8.2.3 F. Hoffmann-La Roche
8.2.4 Ipsen SA
8.3 Other Companies in the Neuroendocrine Carcinoma Therapeutics Market
9 Neuroendocrine Carcinoma Therapeutics- Licensing and Partnership Deals
10 Neuroendocrine Carcinoma Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: GEP-NETs WHO Classification
Table 2:GEP-NETs Classification
Table 3: Historical Prevalence for Neuroendocrine Carcinoma- for Seven Major Markets
Table 4: Forecast Prevalence for Neuroendocrine Carcinoma- for Seven Major Markets
Table 5: Symptoms of Pancreatic NETs/Islet Cell Tumors
Table 6:Diagnosis Techniques by Site of Origin for GI Carcinoid Tumors
Table 7:Diagnosis Tests for Different Types of Functioning Pancreatic Neuroendocrine Tumors
Table 8:TNM Classification of Stomach Carcinoid Tumors
Table 9:TNM Classification of Duodenum Carcinoid Tumors
Table 10:TNM Staging of Appendiceal Carcinoid Tumors
Table 11:TNM Classification of Pancreatic Neuroendocrine Tumors
Table 12:TNM Staging for Pancreatic Neuroendocrine Tumors
Table 13:Chemotherapy Regimens in GEP-NETs Carcinoma
Table 14: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006–2011
Table 15: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Market Forecast ($m), 2011-2019
Table 16:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006–2011
Table 17: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019
Table 18:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006–2011
Table 19: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019
Table 20:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue($m), 2006–2011
Table 21: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019
Table 22:Neuroendocrine Carcinoma Therapeutics Market,Germany, Revenue ($m), 2006–2011
Table 23: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019
Table 24:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue($m), 2006–2011
Table 25: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019
Table 26:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006–2011
Table 27:Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m),
Table 28:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006–2011
Table 29: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019
Table 30:Neuroendocrine Carcinoma Therapeutics – Phase III Pipeline, 2012
Table 31:Neuroendocrine Carcinoma Therapeutics – Phase II Pipeline, 2012
Table 32:Neuroendocrine Carcinoma Therapeutics – Phase I Clinical Pipeline, 2012
Table 33:Neuroendocrine Carcinoma Therapeutics – Preclinical Pipeline, 2012
Table 34: Neuroendocrine Carcinoma Therapeutics –Phase III Promising Drugs in Clinical Development
Table 35:Adverse events of Bevacizumab and Peginterferon alfa-2b
Table 36:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Region/Country, 2012
Table 37:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012
Table 38:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012
Table 39:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Overall Sponsors, 2012
Table 40: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Prominent Sponsors, 2012
Table 41: Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012
Table 42: Advanced Accelerator Applications S.A. – Neuroendocrine Carcinoma Pipeline Product, 2012
Table 43:Novartis AG – Oncology Pipeline Products, 2012
Table 44:Novartis AG – Neuroendocrine Carcinoma Pipeline Product, 2012
Table 45:F. Hoffmann-La Roche- Oncology Pipeline Products, 2012
Table 46:F. Hoffmann-La Roche – Neuroendocrine Carcinoma Pipeline Product, 2012
Table 47:Ipsen SA- Oncology Pipeline Products, 2012
Table 48:Ipsen SA- Neuroendocrine Carcinoma Pipeline Product, 2012
Table 49:Neuroendocrine Carcinoma Therapeutics – Other Future Players, 2012
Table 50:Neuroendocrine Carcinoma Therapeutics, Global, Deals ($m), 2012

1.2 List of Figures
Figure 1: Patient Share of Neuroendocrine Carcinoma- in the Seven Major Markets, 2011
Figure 2:Treatment Algorithm for GEP-NETs
Figure 3:Referral Pathway for GEP-NETs
Figure 4: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Revenue ($m), 2006-2011
Figure 5:Neuroendocrine Carcinoma Therapeutics , Market Share (%), 2011
Figure 6: Neuroendocrine Carcinoma Therapeutics Market, Seven Major Markets, Forecast ($m), 2011-2019
Figure 7:Neuroendocrine Carcinoma Therapeutics, Market Share (%), 2019
Figure 8:Neuroendocrine Carcinoma Therapeutics Market, the US, Revenue ($m), 2006-2011
Figure 9: Neuroendocrine Carcinoma Therapeutics Market, the US, Market Forecast ($m), 2011-2019
Figure 10:Neuroendocrine Carcinoma Therapeutics Market, the UK, Revenue ($m), 2006-2011
Figure 11: Neuroendocrine Carcinoma Therapeutics Market, the UK, Market Forecast ($m), 2011-2019
Figure 12:Neuroendocrine Carcinoma Therapeutics Market, France, Revenue ($m), 2006-2011
Figure 13: Neuroendocrine Carcinoma Therapeutics Market, France, Market Forecast ($m), 2011-2019
Figure 14:Neuroendocrine Carcinoma Therapeutics Market, Germany, Revenue ($m), 2006-2011
Figure 15: Neuroendocrine Carcinoma Therapeutics Market, Germany, Market Forecast ($m), 2011-2019
Figure 16:Neuroendocrine Carcinoma Therapeutics Market, Italy, Revenue ($m), 2006-2011
Figure 17: Neuroendocrine Carcinoma Therapeutics Market, Italy, Market Forecast ($m), 2011-2019
Figure 18:Neuroendocrine Carcinoma Therapeutics Market, Spain, Revenue ($m), 2006-2011
Figure 19: Neuroendocrine Carcinoma Therapeutics Market, Spain, Market Forecast ($m), 2011-2019
Figure 20:Neuroendocrine Carcinoma Therapeutics Market, Japan, Revenue ($m), 2006-2011
Figure 21: Neuroendocrine Carcinoma Therapeutics Market, Japan, Market Forecast ($m), 2011-2019
Figure 22:Neuroendocrine Carcinoma Therapeutics – Drivers and Barriers, 2012
Figure 23:Opportunities and Unmet Need in the GI Carcinoid NETs Therapeutics Market
Figure 24:Opportunities and Unmet Need in Pancreatic NETs Therapeutics Market
Figure 25: Strategic Competitor Assessment of the Major Marketed Products in GI Carcinoid NETs, 2012
Figure 26: Strategic Competitor Assessment of the Major Marketed Products in Pancreatic NETs, 2012
Figure 27: Neuroendocrine Carcinoma Therapeutics Pipeline by Phase of Clinical Development, 2012
Figure 28: Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Mechanism of Action, 2012
Figure 29: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline, 2012
Figure 30: Technology Trends Analytic Framework of the Neuroendocrine Carcinoma Therapeutics Pipeline – Description, 2012
Figure 31:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Region/Country, 2012
Figure 32:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Phase, 2012
Figure 33:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Trial Status, 2012
Figure 34:Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Overall Sponsors, 2012
Figure 35: Neuroendocrine Carcinoma Therapeutics– Clinical Trials by Prominent Sponsors, 2012
Figure 36:Neuroendocrine Carcinoma Therapeutics – Clinical Trials by Top Companies, 2012
Figure 37:GI Carcinoids NETs Therapeutics – Implications for Future Market Competition, 2012
Figure 38:Pancreatic NETs Therapeutics – Implications for Future Market Competition, 2012
Figure 39:Neuroendocrine Carcinoma Therapeutics – Clinical Pipeline by Company, 2012
Figure 40- GlobalData Market Forecasting Model

Advanced Accelerator Applications S.A
Novartis AG
F. Hoffmann-La Roche
Ipsen SA

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos